1. Home
  2. GRDN vs HRMY Comparison

GRDN vs HRMY Comparison

Compare GRDN & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Guardian Pharmacy Services Inc. Class A Common Stock

GRDN

Guardian Pharmacy Services Inc. Class A Common Stock

HOLD

Current Price

$29.35

Market Cap

1.7B

ML Signal

HOLD

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$38.25

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRDN
HRMY
Founded
2004
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Retail-Drug Stores and Proprietary Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
2.0B
IPO Year
2024
2020

Fundamental Metrics

Financial Performance
Metric
GRDN
HRMY
Price
$29.35
$38.25
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
9
Target Price
$32.00
$51.33
AVG Volume (30 Days)
351.5K
768.4K
Earning Date
11-10-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
50.44
EPS
0.28
3.17
Revenue
$1,389,638,000.00
$825,944,000.00
Revenue This Year
$19.50
$20.68
Revenue Next Year
$0.48
$15.93
P/E Ratio
$105.18
$11.68
Revenue Growth
18.68
21.13
52 Week Low
$17.78
$25.52
52 Week High
$37.43
$40.93

Technical Indicators

Market Signals
Indicator
GRDN
HRMY
Relative Strength Index (RSI) 56.79 81.58
Support Level $28.62 $32.77
Resistance Level $29.90 $36.20
Average True Range (ATR) 1.04 1.13
MACD -0.06 0.24
Stochastic Oscillator 62.26 91.87

Price Performance

Historical Comparison
GRDN
HRMY

About GRDN Guardian Pharmacy Services Inc. Class A Common Stock

Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Share on Social Networks: